Abstract
OBJECTIVE. The purpose of this article is to provide a practical review of newly established morphologic tumor response criteria for hepatic colorectal metastasis treated with bevacizumab-containing chemotherapy and a description of the patterns of early recurrence. We also discuss the respective value of these criteria and the Response Evaluation Criteria in Solid Tumors (RECIST). CONCLUSION. RECIST alone are not sufficient to assess response after bevacizumab-containing chemotherapy for hepatic colorectal metastasis. The combined use of RECIST and morphologic criteria is mandatory for optimal evaluation in this population.
Original language | English (US) |
---|---|
Pages (from-to) | W1060-W1066 |
Journal | American Journal of Roentgenology |
Volume | 197 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2011 |
Keywords
- Bevacizumab
- CT morphologic criteria
- Colorectal cancer
- Liver metastases
- RECIST
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging